News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rockland Immunochemicals Awarded Phase I SBIR Funding to Develop Akt/mTOR Signaling Pharmacodynamics Assay



9/27/2010 11:12:10 AM

GILBERTSVILLE, Pa.--(BUSINESS WIRE)--Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop a pharmacodynamic assay to monitor the Akt/mTOR signaling pathway.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES